Clinical Trials Browser

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT04645160 2026-04-07

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Phase 1/2 Recruiting

31 enrolled

Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05868629 2026-04-01

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Recruiting

40 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT06494540 2026-03-30

NAUTIC

Recruiting

600 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT06667141 2026-03-23

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Phase 1 Recruiting

100 enrolled

Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Suspended

366 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

442 enrolled

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

233 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

720 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07064122 2026-03-02

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Phase 1 Recruiting

72 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

63 enrolled

Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05882734 2026-02-17

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Phase 1/2 Active not recruiting

61 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT06308263 2026-01-30

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Phase 1 Active not recruiting

12 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting

30 enrolled

Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT05010031 2026-01-23

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Phase 2 Recruiting

40 enrolled

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

MITO END-4

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

9-ING-41 in Patients With Advanced Cancers

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

NAUTIC

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

PIKALO-1

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change